The Oncosearch | Oncotarget

Therapeutic efficacy of the humanized JAA-F11 anti-Thomsen-Friedenreich antibody constructs H2aL2a and H3L3 in human breast and lung cancer xenograft models Research Paper

Diala Ghazal, Fatma Zalzala, John C. Fisk, Swetha Tati, Loukia G. Karacosta, Susan Morey, James R. Olson, Sally Quataert, Grace K. Dy, Kate Rittenhouse-Olson

Published Oct 7, 2022 · Vol. 13, No. 1 · pp. 1155-1164

Keywords: hJAA-F11, TF-Ag, Thomsen-Friedenreich antigen, tumor immunotherapy, translational oncology

HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs Research Paper

Benigno C. Valdez, Yago Nieto, Bin Yuan, David Murray, Borje S. Andersson

Published Sep 24, 2022 · Vol. 13, No. 1 · pp. 1122-1135

Keywords: poly(ADP-ribosyl)ation, HDAC inhibitors, PARP inhibitors, chemotherapy, hematologic malignancy

Correction: Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer Correction

Bruna Cândido Guido, Douglas Cardoso Brandão, Ana Luisa Augusto Barbosa, Monique Jacob Xavier Vianna, Lucas Faro, Luciana Machado Ramos, Fabíola Nihi, Márcio Botelho de Castro, Brenno A.D. Neto, José Raimundo Corrêa, Sônia Nair Báo

Published Aug 5, 2022 · Vol. 13, No. 1 · pp. 1068-1068

Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma Research Paper

Sujatha Muralidharan, Thibault Kervarrec, Glen J. Weiss, Mahtab Samimi

Published Jul 20, 2022 · Vol. 13, No. 1 · pp. 960-967

Keywords: Merkel cell carcinoma, glypican-3, Merkel cell polyomavirus, outcome

CUDC907, a dual phosphoinositide-3 kinase/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells Research Paper

Julianne Huegel, Christine T. Dinh, Maria Martinelli, Olena Bracho, Rosa Rosario, Haley Hardin, Michael Estivill, Anthony Griswold, Sakir Gultekin, Xue-Zhong Liu, Cristina Fernandez-Valle

Published Jul 2, 2022 · Vol. 13, No. 1 · pp. 890-904

Keywords: fimepinostat, Schwann cell, vestibular schwanomma, merlin, nerve allograft

Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation Research Paper

Raquel Torres-Guzmán, Maria Patricia Ganado, Cecilia Mur, Carlos Marugan, Carmen Baquero, Yanzhu Yang, Yi Zeng, Huimin Bian, Jian Du, Alfonso de Dios, Oscar Puig, María José Lallena

Published Jun 22, 2022 · Vol. 13, No. 1 · pp. 864-875

Keywords: abemaciclib, breast cancer, cell lines, CDK4/6, continuous dosing

Targeting lipid metabolism in the treatment of ovarian cancer Review

Saliha Chaudhry, Stefani N. Thomas, Glenn E. Simmons Jr.

Published May 18, 2022 · Vol. 13, No. 1 · pp. 768-783

Keywords: ovarian cancer, lipid metabolism, biomarkers, microenvironment, fatty acid

CancerOmicsNet: a multi-omics network-based approach to anti-cancer drug profiling Research Paper

Limeng Pu, Manali Singha, Jagannathan Ramanujam, Michal Brylinski

Published May 9, 2022 · Vol. 13, No. 1 · pp. 695-706

Keywords: cancer growth rate, kinase inhibitors, differential gene expression, gene-disease association, cancer-specific networks

Combined treatment with niclosamide and camptothecin enhances anticancer effect in U87 MG human glioblastoma cells Research Paper

Laura Valdez, Benxu Cheng, Daniela Gonzalez, Reanna Rodriguez, Paola Campano, Andrew Tsin, Xiaoqian Fang

Published Apr 22, 2022 · Vol. 13, No. 1 · pp. 642-658

Keywords: glioblastoma, niclosamide, camptothecin, cancer, chemotherapy

Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates Review

Magdalena Cybula, Magdalena Bieniasz

Published Mar 11, 2022 · Vol. 13, No. 1 · pp. 553-575

Keywords: PDX, ovarian cancer, repurposed drugs, tumor models

Transplantation of autologous bone marrow pre-loaded ex vivo with oncolytic myxoma virus is efficacious against drug-resistant Vk*MYC mouse myeloma Research Paper

Nancy Y. Villa, Masmudur M. Rahman, Joseph Mamola, Meaghen E. Sharik, Ana Lemos de Matos, Jacquelyn Kilbourne, Kenneth Lowe, Juliane Daggett-Vondras, Julia D'Isabella, Elizabeth Goras, Marta Chesi, P. Leif Bergsagel, Grant McFadden

Published Feb 21, 2022 · Vol. 13, No. 1 · pp. 490-504

Keywords: myxoma virus, multiple myeloma, combination therapy, autologous transplantation, oncolytic virus

Correction: 2’-Hydroxyflavanone effectively targets RLIP76-mediated drug transport and regulates critical signaling networks in breast cancer Correction

Lokesh Dalasanur Nagaprashantha, Jyotsana Singhal, Hongzhi Li, Charles Warden, Xueli Liu, David Horne, Sanjay Awasthi, Ravi Salgia, Sharad S. Singhal

Published Feb 11, 2022 · Vol. 13, No. 1 · pp. 331-331

ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells Research Paper

Benigno C. Valdez, David Murray, Bin Yuan, Yago Nieto, Uday Popat, Borje S. Andersson

Published Feb 2, 2022 · Vol. 13, No. 1 · pp. 319-330

Keywords: ABT199/venetoclax, busulfan, cyclophosphamide, fludarabine, acute myeloid leukemia

The long winding road to the safer glucocorticoid receptor (GR) targeting therapies Review

Ekaterina A. Lesovaya, Daria Chudakova, Gleb Baida, Ekaterina M. Zhidkova, Kirill I. Kirsanov, Marianna G. Yakubovskaya, Irina V. Budunova

Published Feb 1, 2022 · Vol. 13, No. 1 · pp. 408-424

Keywords: glucocorticoid receptor, glucocorticoids, SEGRAM, REDD1, drug repurposing

GZ17-6.02 and axitinib interact to kill renal carcinoma cells Research Paper

Laurence Booth, Cameron West, Robert P. Moore, Daniel Von Hoff, Paul Dent

Published Jan 28, 2022 · Vol. 13, No. 1 · pp. 281-290

Keywords: GZ17-6.02, axitinib, renal cell carcinoma, autophagy, HDAC

Impact of the glutathione synthesis pathway on sulfasalazine-treated endometrial cancer Research Paper

Kanako Sendo, Manabu Seino, Tsuyoshi Ohta, Satoru Nagase

Published Jan 24, 2022 · Vol. 13, No. 1 · pp. 224-236

Keywords: endometrial cancer, glutathione, sulfasalazine, xCT, cystathionine gamma-lyase

Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning Research Paper

Ignacio Durán, Daniel Castellano, Javier Puente, Lidia Martín-Couce, Esther Bello, Urbano Anido, José Manuel Mas, Luis Costa

Published Jan 20, 2022 · Vol. 13, No. 1 · pp. 237-256

Keywords: machine learning, cabozantinib, renal cell carcinoma, tumour microenvironment, systems biology

Common cancer treatments targeting DNA double strand breaks affect long-term memory and relate to immediate early gene expression in a sex-dependent manner Research Paper

Sydney Weber Boutros, Destine Krenik, Sarah Holden, Vivek K. Unni, Jacob Raber

Published Jan 14, 2022 · Vol. 13, No. 1 · pp. 198-213

Keywords: amifostine, etoposide, double strand breaks, memory, sex

GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells Research Paper

Laurence Booth, Cameron West, Robert P. Moore, Daniel Von Hoff, Paul Dent

Published Jan 6, 2022 · Vol. 13, No. 1 · pp. 92-104

Keywords: GZ17-6.02, palbociclib, 5FU, autophagy, breast cancer

Exploiting protein family and protein network data to identify novel drug targets for bladder cancer Research Paper

Tolulope Tosin Adeyelu, Aurelio A. Moya-Garcia, Christine Orengo

Published Dec 28, 2021 · Vol. 13, No. 1 · pp. 105-117

Keywords: CATH-FunFams, bladder cancer, protein interaction network, drug targets, drug side effects

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

Therapeutic efficacy of the humanized JAA-F11 anti-Thomsen-Friedenreich antibody constructs H2aL2a and H3L3 in human breast and lung cancer xenograft models Research Paper

HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs Research Paper

Correction: Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer Correction

Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma Research Paper

CUDC907, a dual phosphoinositide-3 kinase/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells Research Paper

Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation Research Paper

Targeting lipid metabolism in the treatment of ovarian cancer Review

CancerOmicsNet: a multi-omics network-based approach to anti-cancer drug profiling Research Paper

Combined treatment with niclosamide and camptothecin enhances anticancer effect in U87 MG human glioblastoma cells Research Paper

Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates Review

Transplantation of autologous bone marrow pre-loaded ex vivo with oncolytic myxoma virus is efficacious against drug-resistant Vk*MYC mouse myeloma Research Paper

Correction: 2’-Hydroxyflavanone effectively targets RLIP76-mediated drug transport and regulates critical signaling networks in breast cancer Correction

ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells Research Paper

The long winding road to the safer glucocorticoid receptor (GR) targeting therapies Review

GZ17-6.02 and axitinib interact to kill renal carcinoma cells Research Paper

Impact of the glutathione synthesis pathway on sulfasalazine-treated endometrial cancer Research Paper

Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning Research Paper

Common cancer treatments targeting DNA double strand breaks affect long-term memory and relate to immediate early gene expression in a sex-dependent manner Research Paper

GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells Research Paper

Exploiting protein family and protein network data to identify novel drug targets for bladder cancer Research Paper

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

Therapeutic efficacy of the humanized JAA-F11 anti-Thomsen-Friedenreich antibody constructs H2aL2a and H3L3 in human breast and lung cancer xenograft models Research Paper

HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs Research Paper

Correction: Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer Correction

Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma Research Paper

CUDC907, a dual phosphoinositide-3 kinase/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells Research Paper

Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation Research Paper

Targeting lipid metabolism in the treatment of ovarian cancer Review

CancerOmicsNet: a multi-omics network-based approach to anti-cancer drug profiling Research Paper

Combined treatment with niclosamide and camptothecin enhances anticancer effect in U87 MG human glioblastoma cells Research Paper

Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates Review

Transplantation of autologous bone marrow pre-loaded ex vivo with oncolytic myxoma virus is efficacious against drug-resistant Vk*MYC mouse myeloma Research Paper

Correction: 2’-Hydroxyflavanone effectively targets RLIP76-mediated drug transport and regulates critical signaling networks in breast cancer Correction

ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells Research Paper

The long winding road to the safer glucocorticoid receptor (GR) targeting therapies Review

GZ17-6.02 and axitinib interact to kill renal carcinoma cells Research Paper

Impact of the glutathione synthesis pathway on sulfasalazine-treated endometrial cancer Research Paper

Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning Research Paper

Common cancer treatments targeting DNA double strand breaks affect long-term memory and relate to immediate early gene expression in a sex-dependent manner Research Paper

GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells Research Paper

Exploiting protein family and protein network data to identify novel drug targets for bladder cancer Research Paper